AAAAAA
Results:
1-7
|
Results: 7
Authors:
Birebent, B
Somasundaram, R
Purev, E
Li, WP
Mitchell, E
Hoey, D
Bloom, E
Mastrangelo, M
Maguire, H
Harris, DT
Staib, L
Braumuller, H
Leeser, C
Kuttner, N
Beger, HG
Herlyn, D
Citation: B. Birebent et al., Anti-idiotypic antibody and recombinant antigen vaccines in colorectal cancer patients, CR R ONC H, 39(1-2), 2001, pp. 107-113
Authors:
Harris, DT
Citation: Dt. Harris, Introduction: The evolution of early systemic therapy, SEMIN ONCOL, 28(1), 2001, pp. 1-2
Authors:
Harris, DT
Citation: Dt. Harris, Cord Blood: Stat, SCI AM, 285(2), 2001, pp. 8-8
Authors:
Tsang, TC
Brailey, JL
Vasanwala, FH
Wu, RS
Liu, F
Clark, PR
Meade-Tollin, L
Luznick, L
Stopeck, AT
Akporiaye, ET
Harris, DT
Citation: Tc. Tsang et al., Construction of new amplifier expression vectors for high levels of IL-2 gene expression, INT J MOL M, 5(3), 2000, pp. 295-300
Authors:
Meidenbauer, N
Harris, DT
Spitler, LE
Whiteside, TL
Citation: N. Meidenbauer et al., Generation of PSA-reactive effector cells after vaccination with a PSA-based vaccine in patients with prostate cancer, PROSTATE, 43(2), 2000, pp. 88-100
Authors:
Harris, DT
Sakiestewa, D
Lyons, C
Kreitman, RJ
Pastan, I
Citation: Dt. Harris et al., Prevention of graft-versus-host disease (GVHD) by elimination of recipient-reactive donor T cells with recombinant toxins that target the interleukin2 (IL-2) receptor, BONE MAR TR, 23(2), 1999, pp. 137-144
Authors:
Harris, DT
Matyas, GR
Gomella, LG
Talor, E
Winship, MD
Spitler, LE
Mastrangelo, MJ
Citation: Dt. Harris et al., Immunologic approaches to the treatment of prostate cancer, SEMIN ONCOL, 26(4), 1999, pp. 439-447
Risultati:
1-7
|